ADMA Biologics Inc (NASDAQ:ADMA) Given Consensus Rating of “Hold” by Brokerages

ADMA Biologics Inc (NASDAQ:ADMA) has been assigned a consensus recommendation of “Hold” from the five analysts that are currently covering the stock, Marketbeat.com reports. Three analysts have rated the stock with a hold recommendation and two have assigned a buy recommendation to the company. The average twelve-month price objective among brokers that have covered the stock in the last year is $19.00.

A number of equities analysts recently issued reports on ADMA shares. Zacks Research lowered shares of ADMA Biologics from a “strong-buy” rating to a “hold” rating in a research report on Monday, April 27th. Canaccord Genuity Group dropped their target price on shares of ADMA Biologics from $21.00 to $18.00 and set a “buy” rating on the stock in a research report on Thursday, May 7th. Mizuho dropped their target price on shares of ADMA Biologics from $24.00 to $20.00 and set an “outperform” rating on the stock in a research report on Thursday, May 7th. Cantor Fitzgerald reaffirmed a “neutral” rating on shares of ADMA Biologics in a research report on Thursday, March 26th. Finally, Wall Street Zen lowered shares of ADMA Biologics from a “buy” rating to a “hold” rating in a report on Monday, May 4th.

ADMA Biologics Price Performance

Shares of ADMA Biologics stock opened at $8.41 on Friday. ADMA Biologics has a 1-year low of $7.21 and a 1-year high of $22.37. The firm has a fifty day simple moving average of $11.68 and a 200-day simple moving average of $15.33. The stock has a market capitalization of $2.00 billion, a price-to-earnings ratio of 12.37 and a beta of 0.83. The company has a current ratio of 6.95, a quick ratio of 3.93 and a debt-to-equity ratio of 0.51.

ADMA Biologics (NASDAQ:ADMA) last announced its earnings results on Wednesday, May 6th. The biotechnology company reported $0.19 earnings per share (EPS) for the quarter, hitting analysts’ consensus estimates of $0.19. ADMA Biologics had a net margin of 32.43% and a return on equity of 39.98%. The business had revenue of $114.49 million for the quarter, compared to analyst estimates of $139.98 million. During the same quarter in the previous year, the firm posted $0.11 earnings per share. ADMA Biologics’s revenue was down .3% compared to the same quarter last year. On average, sell-side analysts expect that ADMA Biologics will post 0.84 earnings per share for the current year.

Insider Buying and Selling at ADMA Biologics

In other ADMA Biologics news, Director Steve Elms purchased 7,000 shares of the stock in a transaction on Thursday, March 5th. The shares were purchased at an average price of $15.67 per share, with a total value of $109,690.00. Following the acquisition, the director directly owned 2,038,730 shares of the company’s stock, valued at $31,946,899.10. This represents a 0.34% increase in their position. The transaction was disclosed in a filing with the SEC, which is accessible through this link. Also, COO Kaitlin M. Kestenberg-Messina sold 10,096 shares of the business’s stock in a transaction on Monday, March 9th. The shares were sold at an average price of $15.63, for a total transaction of $157,800.48. Following the completion of the sale, the chief operating officer directly owned 466,600 shares in the company, valued at $7,292,958. This trade represents a 2.12% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders own 3.90% of the company’s stock.

Institutional Investors Weigh In On ADMA Biologics

Several institutional investors and hedge funds have recently bought and sold shares of ADMA. Rothschild Investment LLC grew its holdings in shares of ADMA Biologics by 373.8% in the 3rd quarter. Rothschild Investment LLC now owns 1,895 shares of the biotechnology company’s stock worth $28,000 after purchasing an additional 1,495 shares during the last quarter. Summit Securities Group LLC bought a new stake in shares of ADMA Biologics in the 4th quarter worth about $29,000. Clearstead Advisors LLC grew its holdings in shares of ADMA Biologics by 55.7% in the 3rd quarter. Clearstead Advisors LLC now owns 2,222 shares of the biotechnology company’s stock worth $33,000 after purchasing an additional 795 shares during the last quarter. iSAM Funds UK Ltd bought a new stake in shares of ADMA Biologics in the 3rd quarter worth about $34,000. Finally, RiverPark Advisors LLC bought a new stake in shares of ADMA Biologics in the 3rd quarter worth about $35,000. Institutional investors own 75.68% of the company’s stock.

ADMA Biologics Company Profile

ADMA Biologics, Inc is a biopharmaceutical company headquartered in Ramsey, New Jersey, that focuses on the development, manufacturing and commercialization of specialty plasma-derived biologics for the treatment of primary immunodeficiency and infectious diseases. Leveraging an integrated model that spans plasma collection, fractionation, formulation and fill-finish operations, ADMA Biologics aims to address unmet needs in immune-compromised and high-risk patient populations.

The company’s marketed product portfolio includes BIVIGAM, a human immunoglobulin intravenous (IGIV) therapy approved by the U.S.